Open Access

Erratum to: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer

  • Andrea H Bild1, 2Email author,
  • Joel S Parker3, 4,
  • Adam M Gustafson5,
  • Chaitanya R Acharya2,
  • Katherine A Hoadley3, 4,
  • Carey Anders2,
  • P Kelly Marcom2,
  • Lisa A Carey3, 7,
  • Anil Potti2,
  • Joseph R Nevins2 and
  • Charles M Perou3, 4, 6, 8
Breast Cancer Research201113:406

DOI: 10.1186/bcr2909

Published: 12 July 2011

The original article was published in Breast Cancer Research 2009 11:R55

In our previous publication [1], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [2, 3]). It has recently been determined that the chemotherapy-response signatures in [2] are not reproducible, causing retraction of that article [3]. As such, the results presented in Figure 4 of our original paper [1] are no longer valid.

We believe that the data presented in Figures 1, 2, 3 of our article remain valid. However, as Figure 4 can no longer be considered valid, portions of [1] are no longer applicable, including the Materials and Methods section entitled "Chemosensitivity signatures", the Results section entitled "Genomic signatures that predict response to cytotoxic chemotherapeutics", and other statements in the Abstract, Introduction, Results, Discussion, and Conclusions sections that refer directly or indirectly to the integration of chemotherapy-response signatures into the analytical approach presented in the manuscript. As such, the focus of the manuscript on the utility of an integrated approach using three complementary strategies for gene expression analysis (i.e. breast cancer intrinsic subtype analysis, pathway prediction and chemotherapy-response signatures) should now be interpreted as referring exclusively to the integration of two complementary strategies.

Notes

Declarations

Authors’ Affiliations

(1)
Department of Pharmacology and Toxicology, University of Utah
(2)
Duke Institute for Genome Sciences & Policy, Duke University Medical Center
(3)
Lineberger Comprehensive Cancer Center, University of North Carolina
(4)
Department of Genetics, University of North Carolina
(5)
The Pulmonary Center, Boston University School of Medicine
(6)
Department of Pathology & Laboratory Medicine, University of North Carolina
(7)
Division of Hematology/Oncology, Department of Medicine, University of North Carolina
(8)
Carolina Center for Genome Sciences, University of North Carolina

References

  1. Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res. 2009, 11: R55-10.1186/bcr2344.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006, 12: 1294-1300. 10.1038/nm1491.View ArticlePubMedGoogle Scholar
  3. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR: Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2011, 17: 135-10.1038/nm0111-135.View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2011

Advertisement